Format

Send to

Choose Destination
Eur J Med Chem. 2019 Aug 21;182:111634. doi: 10.1016/j.ejmech.2019.111634. [Epub ahead of print]

Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain.

Author information

1
Laboratory of Medicinal Chemistry, College of Pharmacy, Seoul National University, Seoul 08826, South Korea.
2
Medifron DBT, Sandanro 349, Danwon-Gu, Ansan-City, Gyeonggi-Do 15426, Republic of Korea.
3
Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, 16419, South Korea.
4
Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 20892-4255, USA.
5
Laboratory of Medicinal Chemistry, College of Pharmacy, Seoul National University, Seoul 08826, South Korea. Electronic address: jeewoo@snu.ac.kr.

Abstract

In order to discover a novel type of analgesic, we investigated dual activity ligands with TRPV1 antagonism and mu-opioid receptor affinity with the goal of eliciting synergistic analgesia while avoiding the side effects associated with single targeting. Based on a combination approach, a series of 4-benzyl-4-(dimethylamino)piperidinyl analogues were designed, synthesized and evaluated for their receptor activities. Among them, compound 49 exhibited the most promising dual-acting activity toward TRPV1 and the mu-opioid receptor in vitro. In vivo,49 displayed potent, dose-dependent antinociceptive activity in both the 1st and 2nd phases in the formalin assay. Consistent with its postulated mechanism, we confirmed that in vivo, as in vitro, compound 49 both antagonized TRPV1 and functioned as a mu-opioid agonist. This result indicates that dual-acting TRPV1 antagonist/mu-opioid ligands can be made and represent a new and promising class of analgesic.

KEYWORDS:

Analgesic; Dual-acting mechanism; Mu-opioid receptor; TRPV1

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center